©Zhiguo He
Deal with Laboratoires Théa representing a total value of up to $280 million including clinical, regulatory and commercial conditional milestones, commercial royalties, and development responsibility for Phase
Clermont-Ferrand, France, Wednesday 1 October 2025 – Sepul Bio, an innovative business unit of Théa, dedicated to the advancement of RNA therapies for inherited retinal diseases, has
Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement
Théa and Link Biologics sign a new partnership
Théa and ProQR Therapeutics sign a new partnership
Théa and Olix Pharmaceuticals sign a new partnership
Théa and Gallimedix, Inc sign a new partnership
Théa Open Innovation and CURACLE sign a new partnership
Théa and Coave Therapeutics announce their partnership
Théa and Coave Therapeutics announce their partnership